Why Year-End Is the Perfect Time to Add a Neuropathy Program to Your Practice
As 2025 comes to a close, healthcare providers face a critical decision point. With shrinking insurance reimbursements and rising operational costs putting pressure on practice margins, many physicians are looking for ways to strengthen their financial foundation heading into the new year. Adding a neuropathy treatment program—particularly now—offers a unique opportunity to improve patient outcomes while building a sustainable, high-margin revenue stream.
The Growing Demand for Neuropathy Treatment
Peripheral neuropathy affects millions of Americans, yet effective treatment options remain limited in most primary care and specialty practices. According to research published in Scientific Reports, the prevalence of peripheral neuropathy ranges from 10.4% among middle-aged adults to over 39% in older populations. The OHSU Brain Institute estimates that between 20 and 30 million people in the United States live with some form of peripheral neuropathy, though many cases go undiagnosed.
For patients with diabetes, the numbers are even more striking. Research from the National Institutes of Health indicates that approximately 28% of adults with diabetes in the U.S. have peripheral neuropathy, and roughly half of all diabetic patients will develop the condition during their lifetime.
These statistics represent more than just numbers—they represent patients in your community actively searching for relief from nerve pain, numbness, tingling, and burning sensations. Many have been told there's nothing more that can be done, or they've been prescribed medications that only mask symptoms without addressing the underlying nerve damage.
Why a Cash-Based Neuropathy Model Makes Sense
Traditional insurance-based practice models come with well-documented challenges: delayed reimbursements, claim denials, administrative burden, and shrinking payment rates. According to the Medical Group Management Association, practices must continuously seek ways to diversify income streams and optimize revenue cycles to maintain financial stability.
A cash-based neuropathy program sidesteps many of these obstacles. When patients pay directly for treatment, you receive payment upfront without waiting for insurance approvals or fighting denials. This model also allows you to spend more time with patients and deliver the kind of personalized care that drives better outcomes and stronger patient loyalty.
The Neurogenx treatment system exemplifies this approach. As an FDA-cleared device for chronic nerve conditions, the Neurogenx NervePRO 2.0 delivers improved patient outcomes through a proven, turnkey cash-based model. Leading providers using the system report consistent practice growth, stronger patient referrals, and sustained financial health.
Section 179 Tax Benefits: A Year-End Advantage
One of the most compelling reasons to add a neuropathy program before December 31 is the Section 179 tax deduction. This IRS provision allows healthcare practices to deduct the full purchase price of qualifying medical equipment in the year it's placed into service, rather than depreciating the cost over several years.
For 2025, Section 179 limits allow deductions up to $2.5 million on qualifying equipment purchases. The deduction begins to phase out once total purchases exceed $4 million, making it particularly valuable for small to mid-sized practices.
Here's what this means in practical terms: if your practice purchases equipment for $50,000 and you're in a 35% tax bracket, you could potentially save $17,500 in taxes this year alone. That's money that stays in your practice and can be reinvested in growth, staff, or additional patient services.
The key requirement is timing. To qualify for the 2025 deduction, equipment must be purchased and placed into service by December 31, 2025. This means the device must be delivered, installed, and operational before the calendar year ends. Waiting until January means waiting another full year to realize these tax benefits.
What Makes Neurogenx Different
Not all neuropathy treatments are created equal. The Neurogenx 4000Pro with NervePRO 2.0 firmware represents an innovative approach to neuropathy management. The device delivers biosimilar electronic signals at frequencies up to 60,000 Hz, reaching deep tissue to target nerve pain, tingling, burning, numbness, and other neuropathic symptoms regardless of their origin.
What sets Neurogenx apart is its clinical track record. The treatment delivers relief for 87% of neuropathy patients, according to clinical data. Independent laboratory studies reveal nerve density increases averaging 165.4%, with some cases showing improvements up to 395% after treatment. These aren't just symptomatic improvements—they represent actual nerve fiber regeneration and enhanced sensation.
For providers, this translates into a treatment you can confidently recommend to patients, backed by measurable outcomes and reproducible results.
The Complete Year-End Package
Through December 31, 2025, Neurogenx is offering a comprehensive year-end savings package designed to help practices launch or expand their neuropathy programs with minimal financial risk:
$5,000 off the Neurogenx NervePRO 2.0 – A significant reduction on list price for the FDA-cleared treatment device.
Section 179 tax benefits – Maximize your deduction by purchasing before year-end, keeping more cash in your practice.
Complimentary Marketing Business Solutions Program – Receive expert marketing tools, strategies, and support to launch your neuropathy program at no additional cost.
Deferred payment options – Flexible payment plans allow you to start treating patients and generating revenue without impacting your current cash flow.
Positioning Your Practice for 2026
The healthcare landscape continues to evolve, and practices that adapt strategically will thrive. Adding a neuropathy treatment program positions your practice as a leader in managing chronic nerve conditions—a specialty area with strong patient demand and limited competition in most markets.
Beyond the immediate financial benefits, a successful neuropathy program builds patient loyalty, generates referrals, and creates a reputation for innovative care. Patients who find relief after years of suffering become your strongest advocates.
The combination of year-end tax savings, exclusive pricing, and complimentary business support makes this an ideal time to take action. Every week you wait is another week closer to missing these opportunities—and another week your competitors could be getting ahead.
Take the Next Step
Don't let December 31 pass without exploring how Neurogenx can transform your practice. Contact Neurogenx today at 1 (800) 335-7624 or visit neurogenx.info/year-end to secure your exclusive savings and receive a complimentary marketing kick-start package.
The patients in your community are searching for neuropathy solutions. Position your practice to be the answer—and do it while maximizing your tax benefits before the year ends.
